Physician profile
Mohini Pathria
NPI 1609296268
$2,192.16
in general payments reported to CMS, 2019-2025
21 companies · $74.50 in 2025
The $74.50 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $668 · 2021: $298 · 2022: $418 · 2023: $63.69 · 2025: $74.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $543.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $433.29 | 2019-2025 | |
| Phadia US INC. | $261.35 | 2022 | |
| Novo Nordisk INC | $150.16 | 2019-2021 | |
| Aerin Medical INC. | $139.29 | 2022 | |
| Glaxosmithkline, LLC. | $121.40 | 2019-2021 | |
| Amarin Pharma, INC. | $91.81 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $67.61 | 2019-2021 | |
| Abbvie INC. | $62.25 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $47.63 | 2020-2021 | |
| Lilly USA, LLC | $43.75 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.54 | 2020-2023 | Takhzyro |
| Allergan, INC. | $34.14 | 2019-2020 | |
| Genentech USA, INC. | $30.85 | 2025 | Xolair |
| Pfizer INC. | $29.12 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.26 | 2019-2020 | |
| Biocryst US Sales Co., LLC | $15.46 | 2023 | Orladeyo |
| Neos Therapeutics, Lp | $14.41 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.56 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.60 | 2020 | |
| Alk-Abello, INC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohini Pathria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.